Lack of US Data Stymie Roche’s Earlier-Stage Lymphoma Push for Columvi

Roche and Genentech were unable to sufficiently demonstrate the benefit of using Columvi in an earlier treatment setting for DLBCL in a U.S. population, according to the FDA.